Vocabria patents expiration

VOCABRIA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8410103 VIIV HLTHCARE (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Apr, 2026

(2 years from now)

US10927129 VIIV HLTHCARE N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
Apr, 2026

(2 years from now)

Vocabria is owned by Viiv Hlthcare.

Vocabria contains Cabotegravir Sodium.

Vocabria has a total of 2 drug patents out of which 0 drug patents have expired.

Vocabria was authorised for market use on 21 January, 2021.

Vocabria is available in tablet;oral dosage forms.

Vocabria can be used as treatment of hiv-1 in an adult in combination with rilpivirine.

Drug patent challenges can be filed against Vocabria from 2025-01-21.

The generics of Vocabria are possible to be released after 28 April, 2026.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 21, 2026
New Patient Population (NPP) Mar 29, 2025
M (M) Jan 31, 2025

Drugs and Companies using CABOTEGRAVIR SODIUM ingredient

NCE-1 date: 2025-01-21

Market Authorisation Date: 21 January, 2021

Treatment: Treatment of hiv-1 in an adult in combination with rilpivirine


More Information on Dosage

VOCABRIA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic